BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sanofi Pasteur (SASY.PA) Recalls Tuberculosis Vaccine Over Contamination Concerns


6/18/2012 8:10:07 AM

OTTAWA, June 15, 2012 -- /CNW/ - Health Canada is advising Canadians that Sanofi Pasteur is voluntarily recalling all Bacille Calmette-Guérin (BCG) vaccine on the market because of problems in the manufacturing facility that Health Canada believes may have affected the vaccine quality.

BCG is used to prevent serious complications of tuberculosis (TB) infection, notably for infants and children living in First Nation and Inuit communities at high risk for tuberculosis outbreaks. It is not widely used in Canada and does not prevent TB infection in someone who has already been exposed.

Approximately 1,000 vials of the vaccine have already been kept out of circulation by Sanofi Pasteur, and roughly another 4,700 vials on the market are being immediately recalled.

The Public Health Agency of Canada is investigating options to replace the BCG vaccine. Health Canada will use all of the regulatory tools at its disposal to make a replacement vaccine available while ensuring that safety is not compromised.

For infants who will not be given the BCG vaccine due to this recall, Health Canada staff and community health care workers will continue to provide strong TB program services, ensuring measures are in place to protect children at risk of exposure to TB. Antibiotic treatments are available on the Canadian market to treat tuberculosis even in very young patients.

For those who have recently received the vaccine, the symptoms of a reaction related to the manufacturing problems would likely be mild and would occur within a few days of receiving the vaccine. They would include injection site soreness and mild irritation. Consult with your healthcare practitioner if you are concerned about your health or your child's health after receiving the BCG vaccine.

Three adverse reactions potentially linked to the recalled vaccine lots have been reported to the Public Health Agency of Canada and Health Canada, and all were the kind of mild reactions normally associated with this vaccine.

Health Canada continues to work with Sanofi Pasteur to address the issues in the manufacturing facility that lead to these actions.

Consumers requiring more information about this advisory can contact Health Canada's public enquiries line at (613) 957-2991, or toll free at 1-866-225-0709.

Également disponible en français

SOURCE Health Canada



Read at BioSpace.com
Read at The Star
Read at Metro [San Jose]
Read at CBC

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES